{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:32:43Z","timestamp":1790908363196,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2003,11,5]],"date-time":"2003-11-05T00:00:00Z","timestamp":1067990400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1038\/sj.npp.1300343","type":"journal-article","created":{"date-parts":[[2003,11,5]],"date-time":"2003-11-05T17:24:19Z","timestamp":1068053059000},"page":"221-228","source":"Crossref","is-referenced-by-count":93,"title":["The Selective Serotonin-2A Receptor Antagonist M100907 Reverses Behavioral Deficits in Dopamine Transporter Knockout Mice"],"prefix":"10.1038","volume":"29","author":[{"given":"Alasdair M","family":"Barr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Lehmann-Masten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Paulus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul R","family":"Gainetdinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc G","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,11,5]]},"reference":[{"key":"BF1300343_CR1","doi-asserted-by":"publisher","first-page":"16S","DOI":"10.1016\/S0893-133X(98)00135-3","volume":"21","author":"GK Aghajanian","year":"1999","unstructured":"Aghajanian GK, Marek GJ (1999). Serotonin and hallucinogens. Neuropsychopharmacology 21: 16S\u201323S.","journal-title":"Neuropsychopharmacology"},{"key":"BF1300343_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/S0165-0173(99)00046-6","volume":"31","author":"GK Aghajanian","year":"2000","unstructured":"Aghajanian GK, Marek GJ (2000). Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Rev 31: 302\u2013312.","journal-title":"Brain Res Rev"},{"key":"BF1300343_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/00004714-199808000-00012","volume":"18","author":"B Andree","year":"1998","unstructured":"Andree B, Nyberg S, Ito H, Ginovart N, Brunner F, Jaquet F et al (1998). Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain. J Clin Psychopharmacol 18: 317\u2013323.","journal-title":"J Clin Psychopharmacol"},{"key":"BF1300343_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/026988110201600113","volume":"16","author":"L Barnard","year":"2002","unstructured":"Barnard L, Young AH, Pearson J, Geddes J, O'Brien G (2002). A systematic review of the use of atypical antipsychotics in autism. J Psychopharmacol 16: 93\u2013101.","journal-title":"J Psychopharmacol"},{"key":"BF1300343_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s002130100810","volume":"156","author":"DL Braff","year":"2001","unstructured":"Braff DL, Geyer MA, Swerdlow NR (2001). Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156: 234\u2013258.","journal-title":"Psychopharmacology"},{"key":"BF1300343_CR6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/1098-2396(20010315)39:4<297::AID-SYN1012>3.0.CO;2-Q","volume":"39","author":"M Bubser","year":"2001","unstructured":"Bubser M, Backstrom JR, Sanders-Bush E, Roth BL, Deutch AY (2001). Distribution of serotonin 5-HT(2A) receptors in afferents of the rat striatum. Synapse 39: 297\u2013304.","journal-title":"Synapse"},{"key":"BF1300343_CR7","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S0893-133X(96)00053-X","volume":"15","author":"PW Burnet","year":"1996","unstructured":"Burnet PW, Eastwood SL, Harrison PJ (1996). 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 15: 442\u2013455.","journal-title":"Neuropsychopharmacology"},{"key":"BF1300343_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/BF01276460","volume":"100","author":"ML Carlsson","year":"1995","unstructured":"Carlsson ML (1995). The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse\u2014implications for psychosis. J Neural Transm 100: 225\u2013237.","journal-title":"J Neural Transm"},{"key":"BF1300343_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s007020050144","volume":"106","author":"ML Carlsson","year":"1999","unstructured":"Carlsson ML, Martin P, Nilsson M, Sorensen SM, Carlsson A, Waters S et al (1999). The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice. J Neural Transm 106: 123\u2013129.","journal-title":"J Neural Transm"},{"key":"BF1300343_CR10","first-page":"106","volume":"3","author":"L de Angelis","year":"2002","unstructured":"de Angelis L (2002). 5-HT2A antagonists in psychiatric disorders. Curr Opin Investig Drugs 3: 106\u2013112.","journal-title":"Curr Opin Investig Drugs"},{"key":"BF1300343_CR11","first-page":"123","volume":"2","author":"T de Paulis","year":"2001","unstructured":"de Paulis T (2001). M-100907 (Aventis). Curr Opin Investig Drugs 2: 123\u2013132.","journal-title":"Curr Opin Investig Drugs"},{"key":"BF1300343_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s002130050328","volume":"132","author":"SC Dulawa","year":"1997","unstructured":"Dulawa SC, Hen R, Scearce-Levie K, Geyer MA (1997). Serotonin1B receptor modulation of startle reactivity, habituation, and prepulse inhibition in wild-type and serotonin1B knockout mice. Psychopharmacology 132: 125\u2013134.","journal-title":"Psychopharmacology"},{"key":"BF1300343_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0006-3223(99)00122-5","volume":"46","author":"RR Gainetdinov","year":"1999","unstructured":"Gainetdinov RR, Jones SR, Caron MG (1999). Functional hyperdopaminergia in dopamine transporter knock-out mice. Biol Psychiatry 46: 303\u2013311.","journal-title":"Biol Psychiatry"},{"key":"BF1300343_CR14","doi-asserted-by":"publisher","first-page":"11047","DOI":"10.1073\/pnas.191353298","volume":"98","author":"RR Gainetdinov","year":"2001","unstructured":"Gainetdinov RR, Mohn AR, Bohn LM, Caron MG (2001). Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proc Natl Acad Sci USA 98: 11047\u201311054.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF1300343_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0165-6147(02)02044-8","volume":"23","author":"RR Gainetdinov","year":"2002","unstructured":"Gainetdinov RR, Sotnikova TD, Caron MG (2002). Monoamine transporter pharmacology and mutant mice. Trends Pharmacol Sci 23: 367\u2013373.","journal-title":"Trends Pharmacol Sci"},{"issue":"suppl 2","key":"BF1300343_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1055\/s-2007-979350","volume":"31","author":"MA Geyer","year":"1998","unstructured":"Geyer MA (1998). Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research. Pharmacopsychiatry 31(suppl 2): 73\u201379.","journal-title":"Pharmacopsychiatry"},{"key":"BF1300343_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s002130100811","volume":"156","author":"MA Geyer","year":"2001","unstructured":"Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156: 117\u2013154.","journal-title":"Psychopharmacology"},{"key":"BF1300343_CR18","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/379606a0","volume":"379","author":"B Giros","year":"1996","unstructured":"Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996). Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379: 606\u2013612.","journal-title":"Nature"},{"key":"BF1300343_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0006-3223(97)00321-1","volume":"42","author":"EV Gurevich","year":"1997","unstructured":"Gurevich EV, Joyce JN (1997). Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol Psychiatry 42: 529\u2013545.","journal-title":"Biol Psychiatry"},{"key":"BF1300343_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1037\/0033-295X.87.2.175","volume":"87","author":"HS Hoffman","year":"1980","unstructured":"Hoffman HS, Ison JR (1980). Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input. Psychol Rev 87: 175\u2013189.","journal-title":"Psychol Rev"},{"key":"BF1300343_CR21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0091-3057(01)00746-8","volume":"71","author":"D Hoyer","year":"2002","unstructured":"Hoyer D, Hannon JP, Martin GR (2002). Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71: 533\u2013554.","journal-title":"Pharmacol Biochem Behav"},{"key":"BF1300343_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0166-4328(96)00109-X","volume":"73","author":"D Hoyer","year":"1996","unstructured":"Hoyer D, Martin GR (1996). Classification and nomenclature of 5-HT receptors: a comment on current issues. Behav Brain Res 73: 263\u2013268.","journal-title":"Behav Brain Res"},{"key":"BF1300343_CR23","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1073\/pnas.95.2.735","volume":"95","author":"RL Jakab","year":"1998","unstructured":"Jakab RL, Goldman-Rakic PS (1998). 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci USA 95: 735\u2013740.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF1300343_CR24","first-page":"968","volume":"277","author":"JH Kehne","year":"1996","unstructured":"Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Schmidt CJ (1996). Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277: 968\u2013981.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1300343_CR25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0165-0173(99)00054-5","volume":"31","author":"M Laruelle","year":"2000","unstructured":"Laruelle M (2000). The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev 31: 371\u2013384.","journal-title":"Brain Res Brain Res Rev"},{"key":"BF1300343_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0165-0327(01)00372-X","volume":"71","author":"RD Levitan","year":"2002","unstructured":"Levitan RD, Masellis M, Basile VS, Lam RW, Jain U, Kaplan AS et al (2002). Polymorphism of the serotonin-2A receptor gene (HTR2A) associated with childhood attention deficit hyperactivity disorder (ADHD) in adult women with seasonal affective disorder. J Affect Disord 71: 229\u2013233.","journal-title":"J Affect Disord"},{"key":"BF1300343_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0006-8993(02)02620-3","volume":"947","author":"JF Liegeois","year":"2002","unstructured":"Liegeois JF, Ichikawa J, Meltzer HY (2002). 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res 947: 157\u2013165.","journal-title":"Brain Res"},{"key":"BF1300343_CR28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1046\/j.1471-4159.2000.740693.x","volume":"74","author":"G Lucas","year":"2000","unstructured":"Lucas G, Spampinato U (2000). Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J Neurochem 74: 693\u2013701.","journal-title":"J Neurochem"},{"key":"BF1300343_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0924-977X(00)00077-8","volume":"10","author":"MM Marcus","year":"2000","unstructured":"Marcus MM, Nomikos GG, Svensson TH (2000). Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens: role of 5-HT(2A) and alpha(1)-adrenoceptor antagonism. Eur Neuropsychopharmacol 10: 245\u2013253.","journal-title":"Eur Neuropsychopharmacol"},{"key":"BF1300343_CR30","first-page":"357","volume":"297","author":"LR McMahon","year":"2001","unstructured":"McMahon LR, Cunningham KA (2001). Antagonism of 5-hydroxytryptamine(2a) receptors attenuates the behavioral effects of cocaine in rats. J Pharmacol Exp Ther 297: 357\u2013363.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1300343_CR31","doi-asserted-by":"publisher","first-page":"106S","DOI":"10.1016\/S0893-133X(99)00046-9","volume":"21","author":"HY Meltzer","year":"1999","unstructured":"Meltzer HY (1999). The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21: 106S\u2013115S.","journal-title":"Neuropsychopharmacology"},{"key":"BF1300343_CR32","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0166-4328(96)00090-3","volume":"73","author":"PC Moser","year":"1996","unstructured":"Moser PC, Moran PM, Frank RA, Kehne JH (1996). Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT2A antagonist. Behav Brain Res 73: 163\u2013167.","journal-title":"Behav Brain Res"},{"key":"BF1300343_CR33","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1176\/appi.ajp.157.6.1016","volume":"157","author":"ET Ngan","year":"2000","unstructured":"Ngan ET, Yatham LN, Ruth TJ, Liddle PF (2000). Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: a PET study using [(18)F]setoperone. Am J Psychiatry 157: 1016\u20131018.","journal-title":"Am J Psychiatry"},{"key":"BF1300343_CR34","doi-asserted-by":"publisher","first-page":"17S","DOI":"10.1002\/j.1552-4604.1999.tb05933.x","volume":"39","author":"SJ Offord","year":"1999","unstructured":"Offord SJ, Wong DF, Nyberg S (1999). The role of positron emission tomography in the drug development of M100907, a putative antipsychotic with a novel mechanism of action. J Clin Pharmacol 39: 17S\u201324S.","journal-title":"J Clin Pharmacol"},{"key":"BF1300343_CR35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0091-3057(98)00240-8","volume":"63","author":"MF O'Neill","year":"1999","unstructured":"O'Neill MF, Heron-Maxwell CL, Shaw G (1999). 5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB. Pharmacol Biochem Behav 63: 237\u2013243.","journal-title":"Pharmacol Biochem Behav"},{"key":"BF1300343_CR36","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/BF02245610","volume":"124","author":"RA Padich","year":"1996","unstructured":"Padich RA, McCloskey TC, Kehne JH (1996). 5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats. Psychopharmacology 124: 107\u2013116.","journal-title":"Psychopharmacology"},{"key":"BF1300343_CR37","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1007\/BF02245008","volume":"112","author":"MG Palfreyman","year":"1993","unstructured":"Palfreyman MG, Schmidt CJ, Sorensen SM, Dudley MW, Kehne JH, Moser P et al (1993). Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function. Psychopharmacology 112: S60\u2013S67.","journal-title":"Psychopharmacology"},{"key":"BF1300343_CR38","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/BF02244547","volume":"104","author":"MP Paulus","year":"1991","unstructured":"Paulus MP, Geyer MA (1991). A temporal and spatial scaling hypothesis for the behavioral effects of psychostimulants. Psychopharmacology 104: 6\u201316.","journal-title":"Psychopharmacology"},{"key":"BF1300343_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0006-8993(00)03004-3","volume":"888","author":"EA Pehek","year":"2001","unstructured":"Pehek EA, McFarlane HG, Maguschak K, Price B, Pluto CP (2001). M100,907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex. Brain Res 888: 51\u201359.","journal-title":"Brain Res"},{"key":"BF1300343_CR40","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S0006-3223(01)01184-2","volume":"50","author":"W Perry","year":"2001","unstructured":"Perry W, Minassian A, Feifel D, Braff DL (2001). Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania. Biol Psychiatry 50: 418\u2013424.","journal-title":"Biol Psychiatry"},{"key":"BF1300343_CR41","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0893-133X(01)00333-5","volume":"26","author":"G Porras","year":"2002","unstructured":"Porras G, Di Matteo V, Fracasso C, Lucas G, De Deurwaerdere P, Caccia S et al (2002). 5-HT2A and 5-HT2C\/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 26: 311\u2013324.","journal-title":"Neuropsychopharmacology"},{"key":"BF1300343_CR42","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1523\/JNEUROSCI.21-01-00305.2001","volume":"21","author":"RJ Ralph","year":"2001","unstructured":"Ralph RJ, Paulus MP, Fumagalli F, Caron MG, Geyer MA (2001). Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J Neurosci 21: 305\u2013313.","journal-title":"J Neurosci"},{"key":"BF1300343_CR43","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1523\/JNEUROSCI.19-11-04627.1999","volume":"19","author":"RJ Ralph","year":"1999","unstructured":"Ralph RJ, Varty GB, Kelly MA, Wang YM, Caron MG, Rubenstein M et al (1999). The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J Neurosci 19: 4627\u20134633.","journal-title":"J Neurosci"},{"key":"BF1300343_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s002130050017","volume":"148","author":"G Remington","year":"2000","unstructured":"Remington G, Kapur S (2000). Atypical antipsychotics: are some more atypical than others? Psychopharmacology 148: 3\u201315.","journal-title":"Psychopharmacology"},{"key":"BF1300343_CR45","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/00008877-200006000-00008","volume":"11","author":"B Scatton","year":"2000","unstructured":"Scatton B, Sanger DJ (2000). Pharmacological and molecular targets in the search for novel antipsychotics. Behav Pharmacol 11: 243\u2013256.","journal-title":"Behav Pharmacol"},{"key":"BF1300343_CR46","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/(SICI)1096-8628(20000207)96:1<84::AID-AJMG17>3.0.CO;2-9","volume":"96","author":"A Serretti","year":"2000","unstructured":"Serretti A, Cusin C, Lorenzi C, Lattuada E, Lilli R, Smeraldi E (2000). Serotonin-2A receptor gene is not associated with symptomatology of schizophrenia. Am J Med Genet 96: 84\u201387.","journal-title":"Am J Med Genet"},{"key":"BF1300343_CR47","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0006-8993(97)00316-8","volume":"761","author":"TE Sipes","year":"1997","unstructured":"Sipes TE, Geyer MA (1997). DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum. Brain Res 761: 97\u2013104.","journal-title":"Brain Res"},{"key":"BF1300343_CR48","first-page":"684","volume":"266","author":"SM Sorensen","year":"1993","unstructured":"Sorensen SM, Kehne JH, Fadayel GM, Humphreys TM, Ketteler HJ, Sullivan CK et al (1993). Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266: 684\u2013691.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1300343_CR49","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/00008877-200006000-00011","volume":"11","author":"C Spielewoy","year":"2000","unstructured":"Spielewoy C, Roubert C, Hamon M, Nosten-Bertrand M, Betancur C, Giros B (2000). Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice. Behav Pharmacol 11: 279\u2013290.","journal-title":"Behav Pharmacol"},{"key":"BF1300343_CR50","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/oxfordjournals.schbul.a033326","volume":"24","author":"NR Swerdlow","year":"1998","unstructured":"Swerdlow NR, Geyer MA (1998). Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 24: 285\u2013301.","journal-title":"Schizophr Bull"},{"key":"BF1300343_CR51","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s002130050069","volume":"148","author":"M Talvik-Lotfi","year":"2000","unstructured":"Talvik-Lotfi M, Nyberg S, Nordstrom AL, Ito H, Halldin C, Brunner F et al (2000). High 5HT2A receptor occupancy in M100907-treated schizophrenic patients. Psychopharmacology 148: 400\u2013403.","journal-title":"Psychopharmacology"},{"key":"BF1300343_CR52","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0893-133X(98)00072-4","volume":"20","author":"GB Varty","year":"1999","unstructured":"Varty GB, Bakshi VP, Geyer MA (1999). M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology 20: 311\u2013321.","journal-title":"Neuropsychopharmacology"},{"key":"BF1300343_CR53","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0091-3057(00)00483-4","volume":"68","author":"MG Wadenberg","year":"2001","unstructured":"Wadenberg MG, Browning JL, Young KA, Hicks PB (2001). Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats. Pharmacol Biochem Behav 68: 363\u2013370.","journal-title":"Pharmacol Biochem Behav"},{"key":"BF1300343_CR54","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S0006-3223(97)00424-1","volume":"44","author":"ML Wadenberg","year":"1998","unstructured":"Wadenberg ML, Hicks PB, Richter JT, Young KA (1998). Enhancement of antipsychotic-like properties of raclopride in rats using the selective serotonin2A receptor antagonist MDL 100,907. Biol Psychiatry 44: 508\u2013515.","journal-title":"Biol Psychiatry"},{"key":"BF1300343_CR55","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/S0140-6736(96)90939-3","volume":"347","author":"J Williams","year":"1996","unstructured":"Williams J, Spurlock G, McGuffin P, Mallet J, Nothen MM, Gill M et al (1996). Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group. Lancet 347: 1294\u20131296.","journal-title":"Lancet"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/1300343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/1300343","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/1300343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T02:45:22Z","timestamp":1684205122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1300343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11,5]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["BF1300343"],"URL":"https:\/\/doi.org\/10.1038\/sj.npp.1300343","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,11,5]]}}}